• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccines (Basel) . Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern

tetano

Editor, Senior Moderator
Vaccines (Basel)


. 2022 Apr 8;10(4):578.
doi: 10.3390/vaccines10040578.
Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern


Christopher L D McMillan[SUP] 1 [/SUP], Armira Azuar[SUP] 1 [/SUP], Jovin J Y Choo[SUP] 1 [/SUP], Naphak Modhiran[SUP] 1 [/SUP], Alberto A Amarilla[SUP] 1 [/SUP], Ariel Isaacs[SUP] 1 [/SUP], Kate E Honeyman[SUP] 1 [/SUP], Stacey T M Cheung[SUP] 1 [/SUP], Benjamin Liang[SUP] 1 [/SUP], Maria J Wurm[SUP] 2 [/SUP], Paco Pino[SUP] 2 [/SUP], Joeri Kint[SUP] 2 [/SUP], Germain J P Fernando[SUP] 1 3 [/SUP], Michael J Landsberg[SUP] 1 4 [/SUP], Alexander A Khromykh[SUP] 1 4 [/SUP], Jody Hobson-Peters[SUP] 1 4 [/SUP], Daniel Watterson[SUP] 1 4 [/SUP], Paul R Young[SUP] 1 4 [/SUP], David A Muller[SUP] 1 4 [/SUP]



Affiliations
Free PMC article

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to disrupt essential health services in 90 percent of countries today. The spike (S) protein found on the surface of the causative agent, the SARS-CoV-2 virus, has been the prime target for current vaccine research since antibodies directed against the S protein were found to neutralize the virus. However, as new variants emerge, mutations within the spike protein have given rise to potential immune evasion of the response generated by the current generation of SARS-CoV-2 vaccines. In this study, a modified, HexaPro S protein subunit vaccine, delivered using a needle-free high-density microarray patch (HD-MAP), was investigated for its immunogenicity and virus-neutralizing abilities. Mice given two doses of the vaccine candidate generated potent antibody responses capable of neutralizing the parental SARS-CoV-2 virus as well as the variants of concern, Alpha and Delta. These results demonstrate that this alternative vaccination strategy has the potential to mitigate the effect of emerging viral variants.

Keywords: COVID-19; HD-MAP; HexaPro; S protein; SARS-CoV-2 vaccine; antibodies; cutaneous; intradermal; virus neutralization microneedle patch.
 
Back
Top Bottom